Scope of report
- The report provides a snapshot of the global therapeutic landscape of Cystic Fibrosis.
- The report assesses Cystic Fibrosis pipeline based on highest phase of development, type of sponsor, mechanism of action (MoA), route of administration (RoA), and molecule type.
- The report reviews Cystic Fibrosis pipeline by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The report covers pipeline products based on various stages of development for Cystic Fibrosis ranging from discovery to pre-registration and undisclosed stages.
AstraZeneca, Genentech, Genzyme Corporation, Protease Sciences, Merck & Co, Milkhaus Laboratory, PPL Therapeutics PLC, Lantibio, Inex Pharmaceuticals Corporation, Valentis, Ixion Biotechnology, Vyrex Corporation, GlaxoSmithKline, Cyclacel Pharmaceuticals, Targeted Genetics Corporation, Copernicus Therapeutics, CBR Laboratories, Bayer, Inspire Pharmaceuticals, Genta, Polydex Pharmaceuticals, Boehringer Ingelheim, Chiesi Farmaceutici, Vertex Pharmaceuticals
ICI 200880, Midesteine, CE 1037, TLC C 53, Dornase alfa, ALP 242, DF 1283, AL 721, Ajulemic acid, Cystic fibrosis gene therapy – CFTR-cationic lipid complex, Alpha-1 antitrypsin gene therapy, Uridine triphosphate, L 694458, ML 03, Lancovutide, Tyloxapol, IxC 162, Vantox, Elubrixin, Acetylcysteine lysinate, Depelestat, Seliciclib, DAX
Format: Microsoft Excel
- Single Use: $300
- Site License: $500
- Global License: $800